Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.59 Billion KRW | -92.78% |
| 2022 | 22.13 Billion KRW | 1699.89% |
| 2021 | 1.22 Billion KRW | 37.15% |
| 2020 | 896.59 Million KRW | -49.42% |
| 2019 | 1.77 Billion KRW | 13.03% |
| 2018 | 1.56 Billion KRW | -74.76% |
| 2017 | 6.21 Billion KRW | -70.62% |
| 2016 | 21.15 Billion KRW | -19.84% |
| 2015 | 26.38 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 24.37 Billion KRW | 21.88% |
| 2024 Q1 | 20 Billion KRW | 0.0% |
| 2023 Q2 | 1.94 Billion KRW | -11.03% |
| 2023 Q1 | 2.18 Billion KRW | -90.12% |
| 2023 FY | 1.59 Billion KRW | -92.78% |
| 2023 Q4 | 1.59 Billion KRW | -14.42% |
| 2023 Q3 | 1.86 Billion KRW | -3.97% |
| 2022 Q1 | 21.33 Billion KRW | 1635.09% |
| 2022 FY | 22.13 Billion KRW | 1699.89% |
| 2022 Q4 | 22.13 Billion KRW | -1.55% |
| 2022 Q3 | 22.48 Billion KRW | 4.09% |
| 2022 Q2 | 21.59 Billion KRW | 1.23% |
| 2021 Q3 | 860.04 Million KRW | 6.79% |
| 2021 Q4 | 1.22 Billion KRW | 42.97% |
| 2021 FY | 1.22 Billion KRW | 37.15% |
| 2021 Q1 | 792.67 Million KRW | -11.59% |
| 2021 Q2 | 805.32 Million KRW | 1.6% |
| 2020 Q3 | 1.15 Billion KRW | 0.06% |
| 2020 Q4 | 896.59 Million KRW | -22.06% |
| 2020 FY | 896.59 Million KRW | -49.42% |
| 2020 Q1 | 1.47 Billion KRW | -16.64% |
| 2020 Q2 | 1.14 Billion KRW | -22.19% |
| 2019 Q4 | 1.77 Billion KRW | -18.59% |
| 2019 FY | 1.77 Billion KRW | 13.03% |
| 2019 Q3 | 2.17 Billion KRW | 61.02% |
| 2019 Q1 | 2.4 Billion KRW | 53.35% |
| 2019 Q2 | 1.35 Billion KRW | -43.77% |
| 2018 FY | 1.56 Billion KRW | -74.76% |
| 2018 Q3 | 3.2 Billion KRW | -43.33% |
| 2018 Q4 | 1.56 Billion KRW | -51.07% |
| 2018 Q2 | 5.65 Billion KRW | 0.0% |
| 2017 FY | 6.21 Billion KRW | -70.62% |
| 2016 FY | 21.15 Billion KRW | -19.84% |
| 2015 FY | 26.38 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 88.278% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.209% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 94.649% |
| HANDOK Inc. | 123.78 Billion KRW | 98.708% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -236.074% |
| Yuhan Corporation | 60.23 Billion KRW | 97.346% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.013% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -1470.301% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 98.051% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -170.849% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 73.573% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 91.368% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 87.295% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 88.278% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -1235.952% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 98.679% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 95.004% |
| JW Holdings Corporation | 20.65 Billion KRW | 92.26% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 89.215% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 94.671% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 94.671% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -630.197% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -175.356% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 96.774% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 64.087% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 88.278% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 91.597% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 98.288% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 94.671% |
| Yuhan Corporation | 60.23 Billion KRW | 97.346% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 84.773% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 96.04% |
| Suheung Co., Ltd. | 74 Billion KRW | 97.84% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 94.671% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 61.627% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 85.415% |
| CKD Bio Corp. | 69.43 Billion KRW | 97.697% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 95.376% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 90.086% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -420.701% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -630.197% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 97.783% |
| Boryung Corporation | 151.7 Billion KRW | 98.946% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 97.964% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 73.573% |
| JW Lifescience Corporation | 168 Million KRW | -851.694% |